Mitochondrial Targeted Therapies: Where Do We Stand in Mental Disorders? (original) (raw)

2017, Biological Psychiatry

The neurobiology of psychiatric disorders is still unclear, although changes in multiple neuronal systems, specifically the dopaminergic, glutamatergic and GABAergic systems as well as abnormalities in synaptic plasticity and neural connectivity, are currently suggested to underlie their pathophysiology. A growing body of evidence suggests multifaceted mitochondrial dysfunction in mental disorders, which is in line with their role in neuronal activity, growth, development and plasticity. In this review, we will describe the main endeavors towards development of treatments that will enhance mitochondrial function and their transition into clinical use, in congenital mitochondrial diseases and chronic disorders such as diabetes type I&II, cardiovascular disorders and cancer. In addition, we will discuss the relevance of mitochondrial targeted treatments to mental disorders and their potential to become a novel therapeutic strategy that will improve the efficiency of the current treatments.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact